Ebola virus: The search for vaccines and treatments

Cellular and Molecular Life Sciences

Volumn 58, Issue 12-13, 2001, Pages 1826-1841

  Wilson, J A ^a   Bosio, C M ^a   Hart, M K ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Ebola virus; Filovirus; Immunity

Indexed keywords

DNA VACCINE; VACCINIA VACCINE; VIRUS VACCINE;

DRUG MECHANISM; EBOLA VIRUS; GUINEA PIG; HEMORRHAGIC FEVER; HUMAN; IMMUNITY; INFECTION PREVENTION; INFECTION RATE; NONHUMAN; PROTEIN EXPRESSION; REPLICON; REVIEW; SURVIVAL RATE; VACCINE PRODUCTION;

CAVIA PORCELLUS; EBOLA VIRUS; FILOVIRIDAE; MARBURG-LIKE VIRUSES; PRIMATES; SUS SCROFA; VACCINIA;

EID: 0035197291     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000821     Document Type: Review

References (114)

1. Marburg agent disease: In man
2. Fatal human disease from vervet monkeys
3. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International study team
4. Ebola haemorrhagic fever in Zaire, 1976
5. Outbreak of Ebola hemorrhagic fever, Uganda, August 2000-January 2001
6. Preliminary report: Isolation of Ebola virus from monkeys imported to USA
7. Update: Filovirus infection among persons with occupational exposure to nonhuman primates
8. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995
9. Isolation and partial characterization of a new virus causing acute haemorrhagic fever in Zaire
10. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995
11. A comparative study of strains of Ebola virus isolated from southern Sudan and northern Zaire in 1976
12. Ebola virus: A comparison, at ultrastructural level, of the behaviour of the Sudan and Zaire strains in monkeys
13. Biologic differences between strains of Ebola virus from Zaire and Sudan
14. Experimental inoculation of plants and animals with Ebola virus
15. A search for Ebola virus in animals in the Democratic Republic of the Congo and Cameroon: Ecologic, virologic, and serologic surveys, 1979-1980
16. Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: Arthropod studies
17. Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: Reflections on a vertebrate collection
18. Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic
19. The Uganda Ebola outbreak - Not all negative
20. Transmission of Ebola hemorrhagic fever: A study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995
21. A novel immunohistochemical assay for the detection of Ebola virus in skin: Implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit
22. Filoviridae: Marburg and Ebola viruses
23. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus
24. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure
25. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients
26. Pathogenesis of experimental Ebola virus infection in guinea pigs
27. Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States
28. An analysis of features of pathogenesis in two animal models of Ebola virus infection
29. Pathologic features of filovirus infections in humans
30. Marburg and Ebola hemorrhagic fevers: Does the primary course of infection depend on the accessibility of organ-specific macrophages?
31. Pathology of experimental Ebola virus infection in African green monkeys: Involvement of fibroblastic reticular cells
32. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses
33. The pathology of experimental Ebola virus infection in monkeys
34. Clinical virology of Ebola Hemorrhagic fever (EHF): Virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit
35. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection
36. The Ebola virus VP35 protein functions as a type I IFN antagonist
37. Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses
38. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury
39. Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa GP viral protein
40. Human asymptomatic Ebola infection and strong inflammatory response
41. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: A cytokine working group study
42. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: A pilot study
43. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: Final results of cancer biotherapy research group 94-11
44. Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs
45. Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells
46. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells
47. Differentiation of filoviruses by electron microscopy
48. Sequence analysis of the Ebola virus genome: Organization, genetic elements, and comparison with the genome of Marburg virus
49. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases
50. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing
51. Processing of the Ebola virus glycoprotein by the proprotein convertase furin
52. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus
53. Implication of the proprotein convertases furin, PC5 and PC7 in the cleavage of surface glycoproteins of Hong Kong, Ebola, and respiratory syncytial viruses: A comparative analysis with fluorogenic peptides
54. Release of viral glycoproteins during Ebola infection
55. Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates
56. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis
57. Processing of the Ebola virus glycoprotein
58. Ebola virus glycoprotein: Proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies
59. Epitopes involved in antibody-mediated protection from Ebola virus
60. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity
61. A system for functional analysis of Ebola virus glycoprotein
62. Downregulation of β1 integrins by Ebola virus glycoprotein: Implications for virus entry
63. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein
64. Characterization of Ebola virus entry by using pseudotyped viruses: Identification of receptor-deficient cell lines
65. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses
66. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins
67. Endoproteolytic processing of the Ebola virus envelope glycoprotein: Cleavage is not required for function
68. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses
69. Ebola virus, neutrophils, and antibody specificity
70. Molecular characterization of guinea pig-adapted variants of Ebola virus
71. Descriptive analysis of Ebola virus proteins
72. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems
73. Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus
74. Crystal structure of the matrix protein VP40 from Ebola virus
75. Ebola haemorrhagic fever: Experimental infection of monkeys
76. Animal pathology of filoviral infections
77. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: Implications for patient management
78. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola)
79. Pathogenic potential of filoviruses: Role of geographic origin of primate host and virus strain
80. Filovirus clearance in non-human primates
81. Experimental filovirus infections
82. Ebola virus virulence for newborn mice
83. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
84. The role of the type I interferon response in the resistance of mice to filovirus infection
85. Hematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus
86. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients
87. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: Determinants of survival
88. An introduction to Ebola: The virus and the disease
89. Antiviral therapy of haemorrhagic fevers and arbovirus infections
90. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model
91. Treatment of lethal Ebola virus infection in mice with a single dose of an Sadenosyl-L-homocysteine hydrolase inhibitor
92. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections
93. Attempts to obtain a vaccine against Ebola fever
94. Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with Ebola virus
95. Immunobiological properties of vp24 protein of Ebola virus expressed by recombinant vaccinia virus
96. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo
97. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis
98. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus
99. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins
100. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein
101. Venezuelan equine encephalitis virus replicon vector: Immunogenicity studies with Ebola NP and GP genes in guinea pigs
102. Immunization for Ebola virus infection
103. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge
104. Development of a preventive vaccine for Ebola virus infection in primates
105. Fighting the Ebola virus
106. Infectivity-enhancing antibodies to Ebola virus glycoprotein
107. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections
108. Preparation of hyperimmune horse serum to Ebola virus
109. Creation and study of immunoglobulin to Ebola fever
110. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses
111. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis
112. Recombinant human monoclonal antibodies to Ebola virus
113. Ebola virus can be effectively neutralized by antibody produced in natural human infection
114. Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A